You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information. Switch to the US site. 

This website uses cookies

By continuing to use this website you consent to using cookies. For more information about cookies and how we use them, please see our Privacy Policy.

  1. Home
  2. Insights
  3. Specialist areas
  4. Venous Thromboembolism (VTE) Prevention

Venous Thromboembolism (VTE)

Understanding Venous Thromboembolism (VTE)

A common complication of prolonged immobility

Anyone can develop venous thromboembolism (VTE) regardless of age, gender or ethnicity. It is often the result of a prolonged period of immobility and can appear with little warning, with potentially life-threatening results.

Venous Thromboembolism (VTE)

A worldwide challenge for care environments.

VTE represents a serious and widespread clinical challenge:

  • There are 10 million cases of VTE reported worldwide every year 1 yet, VTE-related death is a largely undocumented, but preventable medical condition.
  • It is responsible for more deaths in Europe than breast cancer, prostate cancers, HIV AIDS and traffic accidents combined2.
  • Around 30% of patients will die within 30 days of VTE while 25% of unexpected inpatient deaths are diagnosed with PE at autopsy3.
  • Around 1/3 of patients with DVT develop post-thrombotic syndrome suffering swelling and pain3 and, for many (25%)4, the resultant chronic ulceration is associated with substantial on-going treatment costs5.
  • In the US, up to $19.1 billion is spent on treatment of long term complications every year following VTE6 .
products1.jpg

VTE prevention

Ensure safe and effective VTE prevention for your patients. We offer a comprehensive range of VTE prevention pumps and garments that ensure you are able to provide safe and reliable VTE prevention for your most vulnerable patients.

Read more about our products

Clincial Guidelines

Given the relatively simple and effective measures available to prevent Venous Thromboembolism (VTE) and improve patient wellness, a number of national and international best practice guidelines and technology reviews have been developed through systematic literature review and expert consensus (1-7).

Read more about clincial guidelines

Patient and Carer Information

DVT (deep vein thrombosis or blood clot in the legs) is a common and quite serious condition that affects millions of people around the world every year. The good news is that the condition is relatively easy to prevent, with the right medical treatment and preventative measures.

Read more abut Patient and Carer Information

Clinical FAQ

This section covers a selection of specific clinical questions that might arise during the day-to-day use of Flowtron® Intermittent Pneumatic Compression (IPC) systems.

Read more about clinical FAQ

Education

Intermittent Pneumatic Compression (IPC) is a safe and effective method for the prevention of Venous Thrombolism (VTE).

Read more about education

Clinical and Economical Evidence

Intermittent Pneumatic Compression (IPC) has proved to be a very safe and effective method for promoting patient wellness, by reducing the immediate and long-term costs associated with Deep Vein Thrombosis (DVT).

Read more about clinical and economical evidence

Bibliographies

The following references refer to the topics discussed on this website. Many of them have downloadable summaries, simply click on the relevant link.

Read more about bibliographies

References:

1. Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaisier N, Waters H, Bates DW. The global burden of unsafe medical care: analytic modeling of observational studies. BMJ Qual Saf 2013; 22;809-15. Retrieved from: http://qualitysafety.bmj.com/content/22/10/809.

2. Cohen AT, Agnelli A, Anderson FA et al. Venous thromboembolism (VTE) in Europe: The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98: 756–764.

3. Beckman MG, Hooper WC, Critchley SE et al. Venous thromboembolism: a public health concern. Am J Prev Med. 2010; 38(4): S495-501 

4. Nelzen O, Bergqvist D, Lindhagen A. Leg ulcer etiology - a cross sectional population study. J Vasc Surg. 1991; 14: 557-64 cited in Nicolaides A, Fareed J, Kakkar A et al. Prevention and treatment of venous thromboembolism - International Consensus Statement. International Angiology. 2013; 32(2): 111-260

5. Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ. 2011; 14(1): 65-74

6. Mahan CE, Borrego ME, Woershing AL et al. Venous thromboembolism: Annualised United States model for total, hospital acquired and preventable costs utilising long-term attack rates. Thromb Haemost. 2012; 108(2): 291-302.